Davis L, Effland R C, Klein J T, Dunn R W, Geyer H M, Petko W W
Chemical Research Department, Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey 08876.
Drug Des Discov. 1992 Feb;8(3):225-40.
A series of 3-substituted-6-fluoro-1,2-benzisoxazoles (II) was synthesized and evaluated for potential antipsychotic activity. Many of the compounds displayed potent antipsychotic-like activity in the apomorphine induced climbing in mice (CMA) or spiroperidol binding assays, and compound 42 (HRP 392, 1-[3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl]-4-(2-methoxyphenyl) piperazine) was selected for more detailed antipsychotic evaluation in a battery of preclinical assays. The results of these studies suggests that 42 is a potential antipsychotic drug with less propensity for EPS than some standard neuroleptics in monkeys. The compound was advanced for toxicological evaluation.
合成了一系列3-取代-6-氟-1,2-苯并异恶唑(II),并对其潜在的抗精神病活性进行了评估。许多化合物在阿扑吗啡诱导的小鼠攀爬(CMA)或螺哌啶醇结合试验中表现出强效的抗精神病样活性,化合物42(HRP 392,1-[3-(6-氟-1,2-苯并异恶唑-3-基)丙基]-4-(2-甲氧基苯基)哌嗪)被选用于一系列临床前试验中进行更详细的抗精神病评估。这些研究结果表明,42是一种潜在的抗精神病药物,在猴子中产生锥体外系反应(EPS)的倾向比一些标准抗精神病药物小。该化合物已进入毒理学评估阶段。